The long range goal of this proposal is to characterize the molecular and functional properties of monoclonal antibodies (MoAb) elicited by antiidiotypic MoAb which bear the internal image of human high molecular weight-melanoma associated antigen (HMW-MAA) and GD3 ganglioside. The latter two antigens are being used as targets for immunotherapy in patients with melanoma. The outlined studies will take advantage of a unique panel of antiidiotypic and antiantiidiotypic MoAb elicited during the previous grant period. We will analyze the genetic control of the humoral anti HMW- MAA immune response elicited y the antiidiotypic MoAb elicited with MoAb MK2-23 which bears the internal image of HMW-MAA. This information may suggest criteria to select patients who are likely to mount an anti HMW-MAA immune response following immunization with MoAb MK2-23. We will define the molecular basis of the specificity of antiantiidiotypic MoAb elicited with MoAb MK2-23 by correlating their antigen binding activity with the sequence of the variable regions of their heavy and light chains. Sequences may be identified which are potentially important for HMW-MAA binding activity of MoAb. We will humanize the mouse antiidiotypic MoAb MK2-23, which is being used as an immunogen in clinical trials, to overcome the problem of the formation of antimouse Ig antibodies. We will analyze the immunogenicity of humanized MoAb MK2-23, since this information will be useful to optimize the immunization schedule in patients with melanoma. We will characterize antiidiotypic MoAb elicited with the anti GD2 ganglioside MoAb MB3.6 and we will identify those which bear the internal image of CD3 ganglioside. We will correlate the sequences of the variable regions of the heavy and light chains of antiidiotypic MoAb with their immunogenic properties to define the structure-function relationship of these molecules. Lastly, we will determine the ability of antiidiotypic MoAb to modulate the immune lysis of melanoma cells mediated by anti GD3 ganglioside antibodies. the outlined studies will provide for the first time information about the structural and functional characteristics of the idiotype cascade in the HMW-MAA and in the GD3 ganglioside systems. Furthermore, the potential role of the idiotypic network in the effect of anti GD3 ganglioside immunity on the course of the disease will be characterized.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037959-10
Application #
3175941
Study Section
Experimental Immunology Study Section (EI)
Project Start
1983-12-01
Project End
1997-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
New York Medical College
Department
Type
Schools of Medicine
DUNS #
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Demanet, Christian; Mulder, Arend; Deneys, Veronique et al. (2004) Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103:3122-30
Ogino, Takeshi; Wang, Xinhui; Ferrone, Soldano (2003) Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 278:33-44
Ko, Eric C; Wang, Xinhui; Ferrone, Soldano (2003) Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol 132:294-309
Wang, X; Luo, W; Foon, K A et al. (2001) Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. Cancer Chemother Biol Response Modif 19:309-26
Ferrone, S; Wang, X (2001) Active specific immunotherapy of malignant melanoma and peptide mimics of the human high-molecular-weight melanoma-associated antigen. Recent Results Cancer Res 158:231-5
Kageshita, T; Hamby, C V; Hirai, S et al. (2000) Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer 89:153-9
Kageshita, T; Hamby, C V; Hirai, S et al. (2000) Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 49:314-8
Marincola, F M; Jaffee, E M; Hicklin, D J et al. (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
Desai, S A; Wang, X; Noronha, E J et al. (2000) Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol 165:3275-83
Wang, X; Luo, W; Ferrone, S (2000) Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen. Medicina (B Aires) 60 Suppl 2:48-50

Showing the most recent 10 out of 122 publications